Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir

AIDS Research and Human Retroviruses- United States

doi 10.1089/aid.2012.0150

Full Text

Abstract

Available in

Date

Authors

Publisher

Mary Ann Liebert Inc

Related search

Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

New England Journal of Medicine
Medicine
2009English

Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project

Infection and Drug Resistance
Infectious DiseasesPharmacology
2019English

Differential Effects of Tenofovir/Emtricitabine and Abacavir/Lamivudine on Human Leukocyte Recruitment

Antiviral Therapy
Infectious DiseasesPharmacology
2012English

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2018English

96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study

Antiviral Therapy
Infectious DiseasesPharmacology
2013English

No Difference in Effectiveness of Treatment Simplification to Boosted or Unboosted Atazanavir Plus Lamivudine in Virologically Suppressed in HIV-1-infected Patients

PLoS ONE
Multidisciplinary
2018English

Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-positive Patients Ingesting Dabigatran

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

Cost-Effectiveness Analysis of Tenofovir/Emtricitabine and Abacavir/Lamivudine in Combination With Efavirenz or Atazanavir/Ritonavir for Treatment-Naive Adults With Hiv-1 Infection in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections With Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy